Figure 5

Cisplatin-treated TRPV1-null mice exhibit alteredbehavioral responses to noxious heat stimuli. (A) Oxaliplatin-treated TRPV1^-/- and wild-type mice show an increase in the number of paw lifts to noxious cold stimuli of -4.2°C in a cold plate assay. (B) Cisplatin and oxaliplatin-treated TRPV1^-/- and wild-type mice exhibit a decreased response threshold to punctate mechanical stimuli to the hind paw in von Frey assay. (C) Cisplatin-treated TRPV1^-/- mice show no noxious heat-evoked hyperalgesia in the hind paw in a radiant heat assay. In contrast, cisplatin-treated wild-type mice develop noxious heat-evoked hyperalgesia. (D) Cisplatin-treated TRPV1^-/- mice show no noxious heat-evoked hyperalgesia in a tail immersion test assay. In contrast, cisplatin-treated wild-type mice develop noxious heat-evoked hyperalgesia. Data represent the mean ± SEM, n = 7 mice/group (*P < 0.05; ***P < 0.001, two-way ANOVA followed with post hoc analysis; two-tailed unpaired T test for genotypes).